Drugs / anti-CD20/CD30-CAR-T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06532643 | Aug 2023 → Sep 2025 overdue | lymphoma | Shanghai First Song Biotechnology Co., LTD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD20/CD30-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06532643 ↗ |
| Modality | Cell therapy | “anti-CD20/CD30-CAR-T cells” NCT06532643 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection” NCT06532643 ↗ |